Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 20/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713137 | 0.87 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL4788371 | 0.87 | BDKRB1 (1.00) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2517990 | 0.86 | BDKRB1 (0.99) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2514690 | 0.83 | BDKRB1 (0.85) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2516501 | 0.82 | BDKRB1 (0.99) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2519629 | 0.82 | BDKRB1 (0.99) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2517746 | 0.81 | BDKRB1 (0.99) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL2516511 | 0.81 | BDKRB1 (0.85) | BDKRB1 | |
| SCHEMBL1712642 | 0.78 | BDKRB1 (1.00) | BDKRB1 | |
| SCHEMBL6405218 | 0.78 | BDKRB1 (1.00) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572209-A4 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO INC (US) | 2006-12-06 | — | — | EP | disclosed |
| EP-1572209-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | Merck & Co., Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| US-6908921-B2 | Quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | SU DAI-SHI (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | MERCK & CO., INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2004054584-A1 | NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS | MERCK & CO., INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020591-A1 | 2-Quinoxalinone derivatives as bradykinin antagonists and novel compounds | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885 |
| US-20040132733-A1 | Novel quinoxalinone derivatives as bradykinin B1 antagonists | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.